Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII.
Malherbe
Stephan
S
Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada.
Tsui
Ban C H
BC
Stobart
Kent
K
Koller
John
J
D000925:Anticoagulants / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D001120:Arginine / Q000031:analogs & derivatives; D001026:Coronary Artery Bypass; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D007223:Infant; D008297:Male; D010875:Pipecolic Acids / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*
D000925:Anticoagulants; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; D005167:Factor VII; D006493:Heparin; D001120:Arginine; C103587:recombinant FVIIa; D015942:Factor VIIa; C031942:argatroban